For more than 10 years, Advicenne has been dedicated to developing innovative, effective and safe treatments for people living with rare renal diseases who have very limited therapeutic options. Thanks to our expertise in reformulation and drug delivery, we are uniquely positioned to develop and make available innovative treatments for both children and adults with rare renal diseases.
At Advicenne we are dedicated to improving patients’ daily health and life. Our employees in France and the United States are committed to tackle the challenge of high unmet medical need to improve quality of life for patients and their caregivers.
Sibnayal® (combination of Potassium citrate and Potassium bicarbonate) was in 2021 approved by the European Medicine Agency and MHRA.
Headquartered in Paris and listed on Euronext Growth (Euronext: ALDVI) since 2022. www.advicenne.com